The revival of a potential drug to fight Alzheimer’s, whose clinical trials had been declared futile just months ago, proved the value of sticking with the search for treatments for the disease when other pharmaceuticals companies are “running away”, according to the chief executive of its developer, Biogen. By announcing on Tuesday that it would seek regulatory approval after all for its drug aducanumab, the US biotech company gave new hope to millions of patients and caregivers — and its shareholders. Read the complete article here (PDF).
- ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news December 10, 2019
- Aducanumab is good; next generation Alzheimer’s disease therapies will be better December 5, 2019
- ProMIS Neurosciences Completes First Closing of Private Placement November 18, 2019
- ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform November 6, 2019
- Executive Chairman Gene William’s Presentation at the HC Wainwright Investor Conference September 10, 2019
- CSO Neil Cashman’s overview of ProMIS’ unique capability to selectively target toxic, misfolded proteins that are root causes of neurodegenerative diseases August 12, 2019